You should read the following discussion and analysis of our financial conditionand results of operations in conjunction with the financial statements and thenotes thereto included elsewhere in this Annual Report on Form 10-K. Some of theinformation contained in this discussion and analysis, including informationwith respect to our plans and strategy for our business and related financing,include forward-looking statements that involve risks, uncertainties andassumptions. These statements are based on our beliefs and expectations aboutfuture outcomes and are subject to risks and uncertainties that could cause ouractual results to differ materially from anticipated results. We undertake noobligation to publicly update these forward-looking statements, whether as aresult of new information, future events or otherwise. You should read the "RiskFactors" and "Special Note Regarding Forward-Looking Statements" sections ofthis Annual Report on Form 10-K for a discussion of important factors that couldcause actual results to differ materially from the results described in orimplied by the forward-looking statements contained in the following discussionand analysis.On September 27, 2019, Ocugen completed its reverse merger with Ocugen OpCo Inc.(formerly known as Ocugen, Inc. ("Former Ocugen")) in accordance with the termsof the Agreement and Plan of Merger and Reorganization, dated as of April 5,2019, by and among Histogenics, Former Ocugen and Restore Merger Sub, Inc., awholly owned subsidiary of Histogenics ("Merger Sub"), as amended (the "MergerAgreement"), pursuant to which Merger Sub merged with and into Former Ocugen,with Former Ocugen surviving as a wholly owned subsidiary of Histogenics (the"Merger"). Immediately after completion of the Merger, Histogenics changed itsname to Ocugen, Inc. For accounting purposes, the Merger is treated as a"reverse asset acquisition" under generally acceptable accounting principles inthe United States ("U.S. GAAP") and Former Ocugen is considered the accountingacquirer. Accordingly, Former Ocugen's historical results of operations replacedthe Company's historical results of operations for all periods prior to theMerger and, for all periods following the Merger, the results of operations ofthe combined company will be included in the Company's financial statements.OverviewWe are a clinical-stage biopharmaceutical company focused on discovering,developing and commercializing transformative therapies to treat the whole eye.Our lead product candidate, OCU300, is a small molecule therapeutic currently inPhase 3 clinical development for patients with ocular redness and discomfortstemming from ocular graft-versus-host disease ("oGVHD"). As of March 20, 2020,we had completed over 95% of planned enrollment of our Phase 3 clinical trialfor OCU300. OCU300 has received Orphan Drug Designation ("ODD") from the U.S.Food and Drug Administration (the "FDA"), and it is the first and only productcandidate to receive that designation for the treatment of symptoms associatedwith oGVHD. oGVHD, a severe chronic autoimmune disease that occurs in up to 60%of allogeneic hematopoietic stem cell transplantation ("HSCT") patients, canresult in light sensitivity, excessive ocular redness, severe ocular pain and,ultimately, vision impairment. We estimate the current prevalence of patientssuffering from oGVHD in the United States to be approximately 63,000. OCU300 isformulated using our proprietary nanoemulsion technology, OcuNanoE-Ocugen's ONEPlatform ("OcuNanoE"), which we believe represents an effective drug deliverymechanism to treat ocular surface disorders. We believe that OcuNanoE providesadditional protection to the ocular surface and the potential for enhancedefficacy compared to traditional formulations. We are the first company to usenanoemulsion technology in the ophthalmology space.We were developing OCU310 for patients with dry eye disease, which is alsoformulated using OcuNanoE. We have completed a Phase 3 clinical trial forOCU310 that was initiated in September 2018. Although the trial showed thatOCU310 is safe and well-tolerated, it did not meet its co-primary endpoints forsymptom and sign. We are no longer pursuing the development of this productcandidate.We are also developing a modifier gene therapy platform to generate therapiesdesigned to fulfill unmet medical needs in the area of retinal diseases,including inherited retinal diseases ("IRDs"). Our modifier gene therapyplatform is being designed to target nuclear hormone receptors ("NHRs"), whichhave the potential to restore homeostasis to the retina. Unlike single-genereplacement therapies, which only target one genetic mutation, we believe thatour gene therapy platform, through its use of NHRs, represents a novel approachin that it may address multiple retinal diseases with one product. Our firstgene therapy candidate, OCU400, received two ODDs from the FDA, one for thetreatment of nuclear receptor subfamily 2 group E member 3 ("NR2E3")mutation-associated retinal diseases and the other for the treatment ofcentrosomal protein 290 ("CEP290") mutation-associated retinal diseases. We areplanning to initiate a Phase 1/2a clinical trial for OCU400 in the next twoyears. Our second gene therapy candidate, OCU410, is being developed to utilizethe nuclear receptor genes RAR-related orphan receptor A ("RORA") for thetreatment of dry age-related macular degeneration ("AMD"). This candidate iscurrently in preclinical development. 85
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Net increase (decrease) in cash, cash equivalents and restricted cash
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Table of Contents
Edgar Online, source Glimpses
See the original post here:
OCUGEN : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - marketscreener.com
- Bio Identical Hormone replacement therapy "alternative medicine" OMT - June 1st, 2010 [June 1st, 2010]
- Healthbeat - Hormone Replacement Therapy - August 5th, 2010 [August 5th, 2010]
- Does Hormone Replacement Therapy increase breast cancer risks? - August 11th, 2010 [August 11th, 2010]
- Hormone replacement therapy increases risk of cancer - October 20th, 2010 [October 20th, 2010]
- Hormone Replacement Therapy Risky For Women - October 20th, 2010 [October 20th, 2010]
- Can Hormone Replacement Therapy Lead To Breast Cancer? - January 31st, 2011 [January 31st, 2011]
- Women Turning To Holistic Hormone Replacement Therapy - February 18th, 2011 [February 18th, 2011]
- Is Hormone Replacement Therapy Dangerous? - March 17th, 2011 [March 17th, 2011]
- Hormone Replacement Therapy Complications - May 8th, 2011 [May 8th, 2011]
- Hormone Replacement Therapy - May 10th, 2011 [May 10th, 2011]
- The New Growth Hormone Replacement Therapy - John Crisler, DO - May 13th, 2011 [May 13th, 2011]
- Suzanne Somers on hormone therapy for menopause, part 2 of 6 - May 20th, 2011 [May 20th, 2011]
- Symptoms of Menopause (Menopause #2) - May 20th, 2011 [May 20th, 2011]
- How to Relieve Menopause Symptoms : Hormonal Replacement Therapy for Menopause - May 20th, 2011 [May 20th, 2011]
- HRT - Hormone Replacement Therapy - May 20th, 2011 [May 20th, 2011]
- What is hormone replacement therapy? - May 20th, 2011 [May 20th, 2011]
- Hormone Replacement Therapy and Breast Cancer - May 20th, 2011 [May 20th, 2011]
- Natural Treatments Instead of Hormone Replacement Therapy - May 20th, 2011 [May 20th, 2011]
- Suzanne Somers on hormone therapy for menopause, part 1 of 6 - May 23rd, 2011 [May 23rd, 2011]
- Hormone Replacement Therapy for post-menopausal women - June 19th, 2011 [June 19th, 2011]
- Joe Rogan talking about hormone replacement therapy 6-14-2011 - June 25th, 2011 [June 25th, 2011]
- Hormone Replacement Therapy and Weight - June 25th, 2011 [June 25th, 2011]
- HRC Hormone Replacement Therapy - June 25th, 2011 [June 25th, 2011]
- Study Hormone Replacement Therapy Increases Breast Cancer Risk - kdka.com - June 25th, 2011 [June 25th, 2011]
- 020 - Neo Hormones - July 1st, 2011 [July 1st, 2011]
- Making Sense of Hormone Replacement Therapy - July 28th, 2011 [July 28th, 2011]
- HRT MTF Transition Report Week 10 - July 29th, 2011 [July 29th, 2011]
- Hormone Replacement - Part 2 - July 30th, 2011 [July 30th, 2011]
- Hormone Replacement - Part 1 - July 30th, 2011 [July 30th, 2011]
- Goldie Lookin Chain - HRT - August 9th, 2011 [August 9th, 2011]
- Natural Hormone Replacement Therapy - September 23rd, 2011 [September 23rd, 2011]
- Testosterone Replacement Therapy (TRT): Optimizing Clinical Outcomes - Michael Aziz, MD - September 24th, 2011 [September 24th, 2011]
- Thyroid Replacement Therapy - Ronald Rothenberg, MD - September 24th, 2011 [September 24th, 2011]
- Dr. Ralph Turner discusses Hormone Replacement Therapy. - September 24th, 2011 [September 24th, 2011]
- 1 year on HRT - September 24th, 2011 [September 24th, 2011]
- The Wiley Protocol - September 24th, 2011 [September 24th, 2011]
- My Journal with Low Testosterone TRT Replacement Therapy - September 24th, 2011 [September 24th, 2011]
- 12 years of HRT: My Transition in photos - September 24th, 2011 [September 24th, 2011]
- Dr. Steven Jepson talks about Bio-identical Hormone Replacment Therapy - September 25th, 2011 [September 25th, 2011]
- Estradiol Valerate Injection HRT (Part 3)of(3) - September 25th, 2011 [September 25th, 2011]
- Study: Post-Menopausal Hormone Therapy Increases Cancer Risk - September 25th, 2011 [September 25th, 2011]
- Bio-identical Hormone Replacement (anti-aging) Therapy - Westchase, Tampa, Florida - September 25th, 2011 [September 25th, 2011]
- natural hormone replacement - September 28th, 2011 [September 28th, 2011]
- 6 Month Hormone Effects (before and after) - September 28th, 2011 [September 28th, 2011]
- Jeff Life, MD - Cenegenics, Hormone Replacement Therapy - September 29th, 2011 [September 29th, 2011]
- Huge - September 30th, 2011 [September 30th, 2011]
- Transsexual hormones,Intramuscular injection, Progynon Depot,Estradiol - October 2nd, 2011 [October 2nd, 2011]
- Dr Whiting on Menopause and the Dangers of HRT - October 12th, 2011 [October 12th, 2011]
- Ahuviya Harel (ADF-Fuensalida) to Start Hormone Replacement Therapy - October 13th, 2011 [October 13th, 2011]
- Clomid Defined - Video - October 14th, 2011 [October 14th, 2011]
- Thyroid Hormone Replacement Therapy - Dr. Denis Rebic - Video - October 14th, 2011 [October 14th, 2011]
- Hormone Replacement Therapy - Video - October 14th, 2011 [October 14th, 2011]
- Dr. Pamela Smith - Bio-Identical Hormone Replacement - Video - October 15th, 2011 [October 15th, 2011]
- Jasper Carrott - Traffic - October 22nd, 2011 [October 22nd, 2011]
- VIDEO: Breast Cancer, Hormone Replacement Therapy Connection - Video - October 24th, 2011 [October 24th, 2011]
- Menopause and Hormone Replacement Therapy with Dr. Sulak - Video - October 24th, 2011 [October 24th, 2011]
- Menopause - October 24th, 2011 [October 24th, 2011]
- bio identical hormone replacement therapy raleigh durcham chaepl hill north carolina - Video - October 24th, 2011 [October 24th, 2011]
- Endocrine Related Hair Loss, Can Hormone Replacement Therapy Help Treat This? Friedman - Video - October 24th, 2011 [October 24th, 2011]
- Dr. Navarro Discusses Bio Identical Hormone Replacement Therapy - Video - October 24th, 2011 [October 24th, 2011]
- Hormone Replacement Therapy by the Book - Eldred Taylor, MD - Video - October 24th, 2011 [October 24th, 2011]
- Sangeeta Pati, MD, FACOG, discusses Hormone Replacement - Video - October 24th, 2011 [October 24th, 2011]
- Active Center's Dr. Gross Discusses Bio-Identical Hormone Replacement Therapy on NEWS 12 NJ - Video - October 28th, 2011 [October 28th, 2011]
- DALLAS ANTI-AGING MEDICINE BIO-IDENTICAL HORMONE THERAPY - Video - October 29th, 2011 [October 29th, 2011]
- Hormone Replacement Therapy and Menopause in Women - Video - November 8th, 2011 [November 8th, 2011]
- Amberen - Natural HRT Alternative Commercial - Video - November 9th, 2011 [November 9th, 2011]
- The Dangers of HRT - Video - November 11th, 2011 [November 11th, 2011]
- The Benefits and Risks of Male Hormone Replacement Therapy - Video - November 16th, 2011 [November 16th, 2011]
- Natural Menopause Treatment - Herbal HRT Alternative - Video - November 23rd, 2011 [November 23rd, 2011]
- Dr. Ian Thorneycroft - Hormone Replacement Therapy - Video - November 24th, 2011 [November 24th, 2011]
- Sarah,MTF Transgender 3months HRT - Video - November 24th, 2011 [November 24th, 2011]
- 26. ftm 1 month on t - Video - November 24th, 2011 [November 24th, 2011]
- Dr. Quint Jardine - Hormone Replacement Therapy with Pellets - Video - November 24th, 2011 [November 24th, 2011]
- 6 Month Changes MTF HRT - Video - November 24th, 2011 [November 24th, 2011]
- Medical Mondays: Will hormone replacement therapy increase my risk of breast cancer? - Video - December 6th, 2011 [December 6th, 2011]
- HRT EXPERIENCES NOT ALL GOOD - Video - December 8th, 2011 [December 8th, 2011]
- Sarah, MTF transgender 9 months HRT - Video - December 9th, 2011 [December 9th, 2011]
- Full: Effect of Testosterone Replacement Therapy on Prostate Tissue in Men with Late-Onset Hypogonadism (Dramatic Health) - Video - December 10th, 2011 [December 10th, 2011]
- Suzanne Somers on hormone therapy for menopause, part 3 of 6 - Video - December 11th, 2011 [December 11th, 2011]
- 1 Year HRT MTF Transition - Video - December 12th, 2011 [December 12th, 2011]